Genuine immunomodulation with dSLIM

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e170-

  Kapp, Kerstin ^a   Kleuss, Christiane ^a   Schroff, Matthias ^a   Wittig, Urghardt ^b  

^a MOLOGEN AG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Cancer immunotherapy; Immune cell activation; Immune modulation; Immuno oncology; Innate immunity; MGN1703; PDC

Indexed keywords

ALPHA INTERFERON; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STEM LOOP IMMUNOMODULATOR; DOUBLE STRANDED DNA; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOMODULATING AGENT; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SIALOADHESIN; SINGLE STRANDED DNA; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER THERAPY; CELL SUBPOPULATION; CPG ISLAND; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DNA CONFORMATION; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; CELL ACTIVATION; CELL ISOLATION; CELL SURFACE; COLORECTAL CARCINOMA; COMPARATIVE STUDY; HUMAN CELL;

EID: 84902650947     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.28     Document Type: Article

References (46)

1. Kawai, T and Akira, S (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
2. Hemmi, H, Takeuchi, O, Kawai, T, Kaisho, T, Sato, S, Sanjo, H et al. (2000). A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
3. Oka, T, Hikoso, S, Yamaguchi, O, Taneike, M, Takeda, T, Tamai, T et al. (2012). Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485: 251-255.
4. Zhang, Q, Raoof, M, Chen, Y, Sumi, Y, Sursal, T, Junger, W et al. (2010). Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107.
5. Hornung, V, Rothenfusser, S, Britsch, S, Krug, A, Jahrsdörfer, B, Giese, T et al. (2002). Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168: 4531-4537.
6. Iwasaki, A and Medzhitov, R (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
7. Guiducci, C, Coffman, RL and Barrat, FJ (2009). Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 265: 43-57.
8. Kawai, T and Akira, S (2007). TLR signaling. Semin Immunol 19: 24-32.
9. Ito, T, Kanzler, H, Duramad, O, Cao, W and Liu, YJ (2006). Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 107: 2423-2431.
10. Colonna, M, Trinchieri, G and Liu, YJ (2004). Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226.
11. Zhang, Z and Wang, FS (2005). Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses. Cell Mol Immunol 2: 411-417.
12. Poeck, H, Wagner, M, Battiany, J, Rothenfusser, S, Wellisch, D, Hornung, V et al. (2004). Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103: 3058-3064.
13. Klinman, DM (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4: 249-258.
14. Krieg, AM (2007). Development of TLR9 agonists for cancer therapy. J Clin Invest 117: 1184-1194.
15. Vollmer, J and Krieg, AM (2009). Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61: 195-204.
16. Krug, A, Rothenfusser, S, Hornung, V, Jahrsdörfer, B, Blackwell, S, Ballas, ZK et al. (2001). Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31: 2154-2163.
17. Verthelyi, D, Ishii, KJ, Gursel, M, Takeshita, F and Klinman, DM (2001). Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 166: 2372-2377.
18. Hartmann, G and Krieg, AM (2000). Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164: 944-953.
19. Hartmann, G, Battiany, J, Poeck, H, Wagner, M, Kerkmann, M, Lubenow, N et al. (2003). Rational design of new CpG oligonucleotides that combine B cell activation with high IFNalpha induction in plasmacytoid dendritic cells. Eur J Immunol 33: 1633-1641.
20. Marshall, JD (2003). Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 73: 781-792.
21. Sato, Y, Roman, M, Tighe, H, Lee, D, Corr, M, Nguyen, MD et al. (1996). Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354.
22. Heikenwalder, M, Polymenidou, M, Junt, T, Sigurdson, C, Wagner, H, Akira, S et al. (2004). Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10: 187-192.
23. Hirsh, V, Paz-Ares, L, Boyer, M, Rosell, R, Middleton, G, Eberhardt, WE et al. (2011). Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 29: 2667-2674.
24. Steinman, RM, Mellman, IS, Muller, WA and Cohn, ZA (1983). Endocytosis and the recycling of plasma membrane. J Cell Biol 96: 1-27.
25. Biesen, R, Demir, C, Barkhudarova, F, Grün, JR, Steinbrich- Zöllner, M, Backhaus, M et al. (2008). Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 58: 1136-1145.
26. York, MR, Nagai, T, Mangini, AJ, Lemaire, R, van Seventer, JM and Lafyatis, R (2007). A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56: 1010-1020.
27. Haas, T, Metzger, J, Schmitz, F, Heit, A, Müller, T, Latz, E et al. (2008). The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 28: 315-323.
28. Vollmer, J, Weeratna, R, Payette, P, Jurk, M, Schetter, C, Laucht, M et al. (2004). Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34: 251-262.
29. Duramad, O, Fearon, KL, Chang, B, Chan, JH, Gregorio, J, Coffman, RL et al. (2005). Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 174: 5193-5200.
30. Guiducci, C, Ott, G, Chan, JH, Damon, E, Calacsan, C, Matray, T et al. (2006). Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203: 1999-2008.
31. Honda, K, Ohba, Y, Yanai, H, Negishi, H, Mizutani, T, Takaoka, A et al. (2005). Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-1040.
32. Diamond, MS, Kinder, M, Matsushita, H, Mashayekhi, M, Dunn, GP, Archambault, JM et al. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208: 1989-2003.
33. Fuertes, MB, Kacha, AK, Kline, J, Woo, SR, Kranz, DM, Murphy, KM et al. (2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208: 2005-2016.
34. Fuertes, MB, Woo, SR, Burnett, B, Fu, YX and Gajewski, TF (2013). Type I interferon response and innate immune sensing of cancer. Trends Immunol 34: 67-73.
35. Asano, K, Nabeyama, A, Miyake, Y, Qiu, CH, Kurita, A, Tomura, M et al. (2011). CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cellassociated antigens. Immunity 34: 85-95.
36. Martinez-Pomares, L and Gordon, S (2012). CD169+ macrophages at the crossroads of antigen presentation. Trends Immunol 33: 66-70.
37. Vesely, MD, Kershaw, MH, Schreiber, RD and Smyth, MJ (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271.
38. Arenberg, DA, Kunkel, SL, Polverini, PJ, Morris, SB, Burdick, MD, Glass, MC et al. (1996). Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184: 981-992.
39. Belperio, JA, Keane, MP, Arenberg, DA, Addison, CL, Ehlert, JE, Burdick, MD et al. (2000). CXC chemokines in angiogenesis. J Leukoc Biol 68: 1-8.
40. Volz, B, Schmidt, M, Kapp, K, Schroff, M, Tschaika, M and Wittig, B. Presented at: 13th Annual Meeting of the American Society of Gene and Cell Therapy, Washington DC, USA, 19-22 May 2010, Mol Ther 18: abstract 822.
41. Grünwald, V, Weikert, S, Schmidt-Wolf, IGH, Hauser, S, Weith, E, Schroff, M, et al. Presented at: 2013 Annual Meeting of the American Society of Clinical Oncology in Rosen Shingle Creek, Orlando, FL, USA, 14-16 February 2013. J Clin Oncol 31: abstract 468.
42. Tschaika, M, Schmoll, HJ, Riera-Knorrenschild, J, Nitsche, D, Trojan, J, Kröning, H, et al. Presented at: 2012 Annual Meeting of the American Society of Clinical Oncology, San Francisco CA, USA, 19-21 January 2012. J Clin Oncol 30: abstract 633.
43. Schmoll, HJ, Riera-Knorrenschild, J, Kroening, H, Mayer, F, Nitsche, D, Ziebermayr, R, et al. Presented at: 2013 Annual Meeting of the European Society of Medical Oncology, Barcelona, Spain, 3-6 July 2013. Ann Oncol 24: abstract O-0012.
44. Schmoll, HJ, Witting, B, Arnold, D, Riera-Knorrenschild, J, Nitsche, D, Kroening, H, et al. (2014). Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised , double-blind, placebo-controlled trial. J Cancer Res Clin Oncol (epub ahead of print).
45. Schmidt, M, Anton, K, Nordhaus, C, Junghans, C, Wittig, B and Worm, M (2006). Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy 61: 56-63.
46. Zuker, M (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.